An ongoing dialogue on HIV/AIDS, infectious diseases,
March 28th, 2010
Kidneys: Fortunately, We Have Two
 Here’s a case over in our Journal Watch: AIDS Clinical Care site:  a man with suspected PCP develops rapidly progressive renal failure after being starting on both empiric PCP treatment with TMP-SMX and ART with TDF/FTC plus darunavir/ritonavir.
Here’s a case over in our Journal Watch: AIDS Clinical Care site:  a man with suspected PCP develops rapidly progressive renal failure after being starting on both empiric PCP treatment with TMP-SMX and ART with TDF/FTC plus darunavir/ritonavir.
The specific questions at the end of the case were:
- What do you think is causing the renal failure?
- Would you continue empiric treatment for PCP or try to confirm the diagnosis?
- If you would continue empiric treatment, would you modify it?
- What would you do with his ART? Specifically, would you continue the tenofovir?
- What would be your preferred alternative regimen?
I ran into the nephrologist Jonathan Winston this weekend, who will providing his take on the case shortly. He asked me what actually happened.
Stay tuned …
[Edit: Outcome of case now posted here.]
                    Categories: Antiretroviral Rounds, Health Care, HIV, Patient Care                    
                    Tags: ART, PCP, renal failure, tenofovir
                    
                You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch 
Infectious Diseases 
      
      Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
- Search this Blog
- Follow HIV and ID Observations Posts via Email
- Archives
- 			
- 
		From the Blog — Most Recent Articles- Two COVID Vaccine Studies — One Actionable, the Other Not So Much October 28, 2025
- What a Difference a Year Makes — with Bonus Halloween Video October 23, 2025
- Another Bad Week for the CDC, and a Personal Note October 16, 2025
- DOTS: Optimism Around a “Negative” Dalbavancin Trial October 10, 2025
- Update on Louie and One Interesting ID Fact October 3, 2025
 
 NEJM Journal Watch — Recent Infectious Disease Articles NEJM Journal Watch — Recent Infectious Disease Articles- Effectiveness of the 2024–2025 Covid-19 Vaccines Examined
- Real-World Performance of Zoster Vaccine
- Cardiac Involvement with Mycoplasma pneumonia: More Common Than Previously Thought
- Observations from ID and Beyond: What a Difference a Year Makes — with Bonus Halloween Video
- RSV Vaccination in Stem-Cell Transplant Recipients
 
- 
        			Tag Cloud- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
 
